Obstetrics & gynaecology

Preclinical study identifies new target for recurrent ovarian cancer

Despite recent advances, ovarian cancer remains the fifth leading cause of cancer-related deaths among women, and there's a critical need for new treatment options, especially for advanced cancers that grow back after standard ...


Pfizer buys biotech firm Seagen for $43 billion

US pharmaceutical giant Pfizer announced Monday that it had reached a deal to buy biotech firm Seagen, specializing in innovative cancer treatment, for $43 billion.

page 1 from 3